These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 27757066)
1. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Eum S; Lee AM; Bishop JR Dialogues Clin Neurosci; 2016 Sep; 18(3):323-337. PubMed ID: 27757066 [TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic studies on the antipsychotic treatment. Current status and perspectives. Gesteira A; Barros F; Martín A; Pérez V; Cortés A; Baiget M; Carracedo A Actas Esp Psiquiatr; 2010; 38(5):301-16. PubMed ID: 21117005 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics in psychiatry: implications for practice. Moore TR; Hill AM; Panguluri SK Recent Pat Biotechnol; 2014; 8(2):152-9. PubMed ID: 25185985 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Arranz MJ; de Leon J Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063 [TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Zhang JP; Malhotra AK Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):9-37. PubMed ID: 21162693 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of psychotropic drug response. Malhotra AK; Murphy GM; Kennedy JL Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenetics/pharmacogenomics in psychiatry]. Ueda M; Ishiguro S; Watanabe T; Saeki Y; Shimoda K Nihon Rinsho; 2010 Jan; 68(1):155-62. PubMed ID: 20077810 [TBL] [Abstract][Full Text] [Related]
9. Fentanyl overdoses and pharmacogenetics. Gerhard GS; Kaniper S; Paynton B Pharmacogenet Genomics; 2020 Jan; 30(1):5-8. PubMed ID: 31651722 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of antipsychoatics. Ozaki N Nagoya J Med Sci; 2004 May; 67(1-2):1-7. PubMed ID: 15279062 [TBL] [Abstract][Full Text] [Related]
11. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Ravyn D; Ravyn V; Lowney R; Nasrallah HA Schizophr Res; 2013 Sep; 149(1-3):1-14. PubMed ID: 23870808 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenetic challenges in the treatment of mental diseases]. Sukhanov VA; Piruzian LA Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(8):83-6. PubMed ID: 15554149 [No Abstract] [Full Text] [Related]
13. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Bousman CA; Jaksa P; Pantelis C Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243 [TBL] [Abstract][Full Text] [Related]
14. Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. Eap CB Dialogues Clin Neurosci; 2016 Sep; 18(3):313-322. PubMed ID: 27757065 [TBL] [Abstract][Full Text] [Related]
15. Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. Huang E; Zai CC; Lisoway A; Maciukiewicz M; Felsky D; Tiwari AK; Bishop JR; Ikeda M; Molero P; Ortuno F; Porcelli S; Samochowiec J; Mierzejewski P; Gao S; Crespo-Facorro B; Pelayo-Terán JM; Kaur H; Kukreti R; Meltzer HY; Lieberman JA; Potkin SG; Müller DJ; Kennedy JL Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26745992 [TBL] [Abstract][Full Text] [Related]
16. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. Saiz-Rodríguez M; Ochoa D; Herrador C; Belmonte C; Román M; Alday E; Koller D; Zubiaur P; Mejía G; Hernández-Martínez M; Abad-Santos F Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):321-329. PubMed ID: 30281924 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics-Guided Advances in Antipsychotic Treatment. Islam F; Men X; Yoshida K; Zai CC; Müller DJ Clin Pharmacol Ther; 2021 Sep; 110(3):582-588. PubMed ID: 34129738 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. Ozdemir V; Basile VS; Masellis M; Kennedy JL J Biochem Biophys Methods; 2001 Jan; 47(1-2):151-7. PubMed ID: 11179771 [TBL] [Abstract][Full Text] [Related]
20. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. de Leon J; Susce MT; Pan RM; Koch WH; Wedlund PJ J Clin Psychopharmacol; 2005 Oct; 25(5):448-56. PubMed ID: 16160620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]